Review | GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with Type 2 Diabetes.
13 Dec, 2022 | 14:29h | UTCGLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes – Circulation (free for a limited period)